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ABSTRACT
CONTEXT AND OBJECTIVE: The possible role of adhesion molecules in early breast carcinogenesis has 
been shown in the literature. We aimed to analyze early adhesion imbalances in non-nodular breast le-
sions and their association with precursor lesions, in order to ascertain whether these alterations exist and 
contribute towards early carcinogenesis. 
DESIGN AND SETTING: Retrospective cross-sectional study based on medical records at a private radio-
logical clinic in São Paulo, Brazil.
METHODS: We retrospectively reviewed the medical records of all consecutive women attended be-
tween August 2006 and July 2007 who presented mammographic evidence of breast microcalcifications 
classified as Breast Imaging Reporting and Data System Atlas (BI-RADS) type 4. These women underwent 
stereotaxic biopsy. Clinical, radiological and pathological data were collected, and immunohistochemical 
assays searched for claudin, paxillin, FRA-1 and HER-2. 
RESULTS: Over this period, 127 patients were evaluated. Previous BI-RADS diagnoses showed that 69 cases 
were in category 4A, 47 in 4B and 11 in 4C. Morphological assessment showed benign entities in 86.5%. 
Most of the benign lesions showed preserved claudin expression, associated with paxillin (P < 0.001). 
Paxillin and HER-2 expressions were correlated. FRA-1 expression was also strongly associated with HER-2 
expression (P < 0.001).
CONCLUSIONS: Although already present in smaller amounts, imbalance of adhesion molecules is not 
necessarily prevalent in non-nodular breast lesions. Since FRA-1 expression reached statistically significant 
correlations with radiological and morphological diagnoses and HER-2 status, it may have a predictive role 
in this setting. 
RESUMO
CONTEXTO E OBJETIVO: A literatura tem mostrado a importância de moléculas de adesão na carcinogê-
nese precoce de mama. Objetivamos analisar desequilíbrios precoces de adesão em lesões não nodulares 
da mama e associação com lesões precursoras, a fim de verificar se essas alterações existem e contribuem 
com a carcinogênese.
TIPO DE ESTUDO E LOCAL: Estudo retrospectivo baseado em prontuários médicos, numa clínica radio-
lógica privada em São Paulo, Brasil.
MÉTODOS: Revisamos retrospectivamente prontuários de todas as mulheres consecutivamente aten-
didas com evidência mamográfica de microcalcificações mamárias, classificadas como tipo 4 do Breast 
Imaging Reporting and Data System Atlas (BI-RADS) entre agosto de 2006 e julho de 2007. Elas foram sub-
metidas a biópsia estereotáxica. Dados clínicos, radiológicos e histopatológicos foram coletados e ensaios 
de imunoistoquímica procuraram por claudina, paxilina, HER-2 e FRA-1.
RESULTADOS: No período, 127 pacientes foram avaliadas. Diagnósticos de BI-RADS anteriores tinham 69 
casos na categoria 4A, 47 em 4B, e 11 em 4C. A avaliação morfológica mostrou entidades benignas em 
86,5%. A maioria das lesões benignas mostrou expressão preservada de claudina, associada a paxilina 
(P < 0,001). Expressões de paxilina e HER-2 foram correlacionadas. Expressão de FRA-1 associou-se à de 
HER-2 (P < 0,001).
CONCLUSÕES: Embora já presente em menor quantidade, o desequilíbrio de moléculas de adesão não 
é necessariamente prevalente em lesões mamárias nodulares e talvez a expressão de FRA-1 possa ter 
um papel preditivo neste cenário, uma vez que atingiu correlações estatisticamente significativas com o 
diagnóstico radiológico e morfológico e com o status de HER-2.
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INTRODUCTION
Precursor lesions of the breast are considered to be entities with 
high potential to progress toward neoplastic transformation, but 
they lack the ability to invade and metastasize and, in this sense, 
are premalignant.1 This broad concept includes most of the diag-
nostic categories exhibiting atypia, such as atypical ductal hyper-
plasia (ADH), atypical lobular hyperplasia (ALH), ductal car-
cinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). 
Although presence of atypia alone is a robust marker for associa-
tion with cancer,2-4 some other lesions not necessarily harboring 
atypia or hyperplasia, such as microglandular adenosis and papil-
lary lesions, have also been associated with invasive carcinoma.5-7 
Recently, microarray analysis on the triple negative subtype of 
ductal invasive carcinomas has indicated that actually there is a 
subset of these cases that does not express claudins. These cases 
were described as “claudin-low” and were characterized by statis-
tically significantly worse prognosis.8
Approximately 23 proteins have already been described 
as members of the claudin family, and these are essential for 
the tight junctions (TJs) that form between epithelial cells and 
between endothelial cells.9 They play crucial roles in controlling 
paracellular transport and in maintaining cell polarity.10 These 
findings shed light on the importance of adhesion molecules and 
their possible role in early breast carcinogenesis. Loss of claudin 4 
has already been reported in cases of lobular in situ carcinoma.11
However, cell adhesion is not limited to the claudin system. 
Several complex molecular schemes contribute to cell adhe-
sion, such as cadherins, integrins and CD4, which have pre-
viously been studied in relation to breast cancer. Other than 
these important components of the cell adherence system, 
some novel mechanisms are directly or indirectly involved in 
cell adhesion, cell stability and prevention of cell migration. 
Focal adhesion sites contain multiple structural proteins such 
as talin, paxillin and focal adhesion kinase (FAK).12 Paxillin 
is an adaptor protein with an important role in cell spreading 
and motility,13 and is located in the region of cell contact with 
the underlying extracellular matrix. In the physiological state, it 
functions as an adaptor protein that recruits several cytoskeleton 
and signaling proteins into a complex, thereby enabling transmis-
sion of coordinated downstream signals.14 Tyrosine phosphoryla-
tion of paxillin has been observed following integrin-dependent 
cell adhesion to extracellular matrix proteins, thus implicating 
paxillin in integrin-mediated signaling and focal adhesion for-
mation.14,15 Few reports have described paxillin distribution in 
breast tissue and ductal carcinomas.
In addition, while mediating cell adhesion, many cell adhe-
sion molecules that have already been described act as tumor sup-
pressors. Disrupted cell-cell or cell-extracellular matrix (ECM) 
adhesion significantly contributes towards uncontrolled cell 
proliferation and progressive distortion of normal tissue archi-
tecture.16 In this regard, another molecular pathway involved 
in cell adhesion, motility and invasion, with a potential role in 
breast cancer, is the AP-1 FRA-1 family.17,18 A recent study has 
shown that high frequency of FRA-1 in ductal carcinoma in situ 
may be associated with early events in breast carcinogenesis, 
since the frequency of FRA-1 expression in invasive cancer was 
lower than the frequency of these in situ lesions.19 Interestingly, 
there are several reports in the literature regarding interactions 
between HER-2 expression (one of the most important receptor 
kinase growth factors in breast cancer) and adhesion molecules. 
HER-2 overexpression has previously been reported to be asso-
ciated with claudin 420 and paxillin expression21 in breast carci-
nomas, which led us to further investigate whether, in our set of 
non-nodular breast lesions, this association would be confirmed.
OBJECTIVES
Our aim was therefore to analyze possible early adhesion imbal-
ances by assessing these markers (claudin, paxillin, HER-2 and 
FRA-1) in non-nodular breast lesions and their possible association 
with precursor lesions, in order to ascertain whether these altera-
tions might be present and contribute towards early carcinogenesis. 
METHODS
The medical records of all consecutive women attended between 
August 2006 and July 2007 who presented non-palpable primary 
breast lesions with mammographic evidence of breast microcalci-
fications and clinically suspicions were identified from the archives 
of a private radiological diagnostic clinic (CURA Diagnostics, São 
Paulo, Brazil), and retrospectively reviewed. The patients were 
referred for further core biopsy or vacuum-assisted biopsy sam-
pling, and their radiological initial and final classifications were 
registered. The Ethics Committee of the Federal University of São 
Paulo (Universidade Federal de São Paulo, Unifesp) approved this 
study (protocol CEP 0002/08). The patients gave their informed 
consent for the diagnostic procedures before inclusion in this 
retrospective study. The inclusion criteria were that the patients 
should present primary non-nodular breast lesions, previously 
classified as Breast Imaging Reporting and Data System Atlas 
(BI-RADS) type 4, and have undergone further radiological diag-
nosis, with morphological sampling for surgical pathological 
diagnosis. All the cases were objectively analyzed by two observ-
ers (trained radiologists). In the event of discordance regarding 
the classification, they worked to reach a consensus. Patients with 
histories of preoperative treatment with chemotherapy or radio-
therapy for other reasons were excluded. Only the patients whose 
paraffin blocks and clinical data were available for further analysis 
were included. Clinical, radiological and morphological data were 
collected. Morphological diagnoses were assessed in accordance 
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with World Health Organization (WHO) guidelines and grouped 
as benign, premalignant or malignant (ductal carcinoma in situ 
and invasive carcinoma). 
Biopsy method 
Stereotaxic vacuum-assisted core biopsy was performed for his-
topathological analysis, using an 11-gauge needle and a vac-
uum-assisted breast biopsy device (Mammotome Biopsy System, 
Johnson & Johnson Ethicon Endo-Surgery), under local injection 
anesthesia (lidocaine in association with 2% epinephrine). The 
patient was positioned according to the location of the targeted 
breast calcifications, always attempting to use the shortest path 
to reach the target area. X-rays were produced before and after 
obtaining specimens. Needle insertion was aimed towards the 
microcalcifications and, in cases of multiple foci, the most sus-
picious group according to the radiological appearance was cho-
sen. The radiologist sought to obtain 15 to 18 specimens for his-
topathology. After concluding the biopsy procedure, a titanium 
clip was inserted, thus marking the biopsied area. Before being 
discarded, the needle was washed and the material remaining in 
the tubes was collected and subjected to further centrifugation. 
Morphological assessment
All the specimens were identified and properly labeled with 
the patient’s data. The samples were radiographed to ascertain 
whether microcalcifications were present, and were packaged in 
vials with 10% buffered formalin. The specimens were then pro-
cessed and embedded in paraffin blocks, and slides of thickness 
5 microns were obtained and stained with hematoxylin-eosin. 
Further sections were subjected to immunohistochemical assays.
On morphological examination, the following catego-
ries of benign lesions were noted: changes associated with 
benign fibrocystic breast disease, fibroadenomas, papillo-
mas and benign tumors such as lipoma and adenomyolipoma. 
Proliferative  lesions were reported as typical or atypical hyper-
plasia. Malignant lesions were classified as in situ, microinvasive 
or infiltrative carcinomas. Along with the histological diagnosis, 
the histological grade and percentage of the sample affected by 
the lesion were reported. A single experienced pathologist exam-
ined all the cases and was blinded to the imaging results (AFL).
Immunohistochemistry 
Control tissues were included in each reaction. Whole 5-μm tis-
sue sections from each block were subjected to each essay (for 
claudin, paxillin, HER-2 and FRA-1), cut and transferred to 
silanized slides, and left to dry overnight at 56 ºC. The next day, 
the slides were dewaxed in xylene, rehydrated in graded alco-
hol and washed with water. Antigen retrieval was performed 
using a pressure cooker and 10 mM citrate buffer (pH 6.0). 
The samples were quenched with 6% hydrogen peroxide and 
incubated overnight at 4 ºC with different antibodies, to be exam-
ined using immunohistochemistry. The following day, the slides 
were rinsed with PBS and incubated with the secondary antibody, 
for 30 min at 37 ºC. The slides were rinsed again with phosphate 
buffered saline (PBS) and incubated with polymer (Novolink 
Max Polymer cat# RE7260-K, Novocastra Lab, Newcastle upon 
Tyne, UK) for 30 min at 37 ºC. The slides were developed with 
100 mg% DAB as the chromogen, with 0.06% hydrogen peroxide, 
and counterstained with Harris hematoxylin. Positive and nega-
tive control slides were included. The negative control was a slide 
from which the primary antibody had been omitted. Table  1 
presents the primary antibodies and dilution rates utilized. 
All reactions were performed in the Pathology Department of A. 
C. Camargo Hospital, São Paulo. 
Claudin-4, paxillin and HER-2 membrane expression were 
assessed by identifying ductal cells from their chicken-wire pat-
tern staining, and were classified using the standard HER-2 clas-
sification system of Herceptest, as 1 to 3+. FRA-1 showed nuclear-
exclusive and diffuse staining. Lesions were defined as positive if at 
least 10% of the true neoplastic tumor cells expressed the protein. 
Radiological assessment 
The initial mammograms brought by patients from other ser-
vices, including the BI-RADS 4 classification, were reviewed. All 
the cases were analyzed by two observers (trained radiologists) 
and were objectively reclassified in accordance with the fourth 
edition of BI-RADS. In the event of discordant classification, the 
two observers worked together to reach a consensus.
Statistical analysis
Spearman’s rank test was used to estimate the relationships 
between staining patterns of different antibodies. The correla-
tion between antigen expression and other parameters was stud-
ied using Pearson’s chi-square or Fisher’s exact test. The numbers 
of false-positive and false-negative mammograms and the num-
ber of examinations with full agreement between the BI-RADS 
(fourth edition) classification and the histopathological findings 
were calculated. Associations between clinical, pathological and 
Antibodies Clones Titers Producer
FRA-1 (C12) Monoclonal in mice 1:50 Santa Cruz, cat# sc28310, Santa Cruz, CA, USA
Claudin-4 Polyclonal in rabbit 1:100 Affinity Bioreagents, cat# PA1-20906, Golden, CO, USA
Paxillin Monoclonal in mice 5H11 1:400 LabVision, cat# MS404, Fremont, CA, USA
Table 1. Antibodies, clones and titers used in the immunohistochemical assay
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radiological variables were evaluated using Fisher’s exact test or 
the chi-square test, as appropriate. Two-sided P values less than 
0.05 were considered statistically significant. All the analyses 
were carried out using the SAS 9.1 software (Statistical Analysis 
System, Cary, NC, USA).
RESULTS
During the study period, 127 patients were evaluated and ful-
filled the inclusion criteria for this study. Among these 127 
patients, the previous BI-RADS diagnoses included 69 cases of 
category 4A, 47 of 4B, and 11 of 4C. The histopathological eval-
uation defined the majority of the cases included (86.5%) as 
benign entities. These included 37 cases of nonspecific functional 
and cystic alterations, one case of papilloma, one case of fibroad-
enoma and 28 cases of usual ductal hyperplasia. Atypical hyper-
plasia was found in five cases and carcinoma (in situ or invasive) 
was present in the remaining 16 cases. The distribution of these 
results is detailed in Table 2 (above). 
Most of the benign lesions showed preserved claudin-4 
expression (Table 3). In normal breast tissue or mammary glands 
presenting mild dysfunctional alterations such as fibroadenosis 
or fibrosclerosis, claudin expression was present in ductal cells, 
with a membrane pattern comparable to HER-2 staining. Usually, 
all mature ductal cells are positive, but the staining is not uni-
formly distributed, since some cells are strongly positive and oth-
ers only moderately so. 
We found the normal tissue pattern commonly equiva-
lent to category 2+ of the ASCO/USCAP (American Society 
of Clinical Oncology/United States and Canadian Academy of 
Pathology) classification for HER-2 expression, with up to 30% 
of the cells strongly positive, among the other 70% with discon-
tinuous positivity. By observing the scope of different alterations 
on the benign diagnostic samples, we could see that apocrine 
metaplasia was almost always totally negative for claudin-4 and 
extended areas of adenosis were usually negative. On the con-
trary, microglandular adenosis was strongly positive. Atrophic 
cells from cystic ducts or dysfunctional postmenopausal women 
are also negative.
We also noticed that lactation-type alteration was negative 
for claudin-4 and, amazingly, within the papilloma present in the 
study, claudin-4 expression was confined to the surface epithelia, 
while the bulk and inner layer were negative. Columnar altera-
tions are usually negative for claudin-4, but the few examples of 
flat atypia in our samples showed a markedly 3+ pattern of clau-
din-4 expression. 
The usual type of hyperplasia showed variable results regard-
ing claudin-4 expression. Most of the cases were positive, but the 
intensity and percentage of positive cells were usually lower than 
in cases with atypia present. As in the few cases harboring foci of 
flat atypia, atypical ductal hyperplasia showed strong claudin-4 
expression, along with the majority of the ductal carcinoma in situ 
samples. All but one of the atypical and malignant cases were pos-
itive for claudin-4 (20/21), although without reaching statistical 
significance for morphological or radiological diagnosis (Table 4). 
Figure 1 shows a strongly 3+ positive claudin-4 ductal carcinoma 
in situ case. 
Since the association between claudin-4 expression and 
HER-2 overexpression had previously been reported in breast 
carcinomas,20 we investigated whether this association would 
be confirmed in our set of non-nodular breast lesions. We 
found that HER-2 expression marginally correlated with clau-
din-4 (P = 0.0734; Table 5).
Variable
BI-RADS
Total P-value
4A 4B or 4C
Histopathological diagnosis
Benign 62 (89.9%) 44 (75.9%) 106 (83.5%)
0.0387ADH (atypical ductal hyperplasia) 3 (4.3%) 2 (3.4%) 5 (3.9%)
Malignant (in situ and invasive) 4 (5.8%) 12 (20.7%) 16 (12.6%)
Total 69 (100%) 58 (100%) 127 (100%)
Table 2. Histopathological and radiological diagnoses of 127 samples from non-nodular breast lesions
BI-RADS = Breast Imaging Reporting and Data System Atlas.
Variable Total
FRA-1
Negative 76 (598%)
Positive 51 (40.2%)
Total 127 (100.0%)
HER-2
Negative 109 (85.8%)
Positive 18 (14.2%)
Total 127 (100.0%)
Claudin
Negative 18 (14.2%)
Positive 109 (85.8%)
Total 127 (100.0%)
Paxillin
Negative 62 (48.,8%)
Positive 65 (51.2%)
Total 127 (100.0%)
Table 3. Frequencies of FRA-1, claudin and paxillin in 127 non-
nodular breast lesions 
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Among the other proteins evaluated, claudin 4 expression 
was associated with paxillin (P < 0.001; Table 4). Paxillin 
expression was detected uniformly in all normal breast tis-
sue (Figure  2). Its distribution correlated with the epithelial 
layers, such that the basal cells tended to be more positive 
than the luminal elements. However, the pattern was similar 
to that of HER-2 expression, i.e. more staining that was more 
membrane-based than cytoplasmic. In preserved breast ele-
ments, paxillin expression was delicate, and finer than the 
chicken-wire membrane-based HER-2 pattern. The basal 
membrane was always positive, as were the myoepithelial 
cells. Some functional alterations like apocrine metaplasia 
and columnar alterations showed diminished or absent pax-
illin expression, and adenosis and fibrosclerosis tended to 
maintain paxillin but in a rather diffuse and weak cytoplas-
mic pattern, with fewer membrane reactive spots. Presence 
of atypia conferred stronger and homogeneous evidence of 
paxillin in affected cells. Paxillin expression did not corre-
late with the morphological or radiological results (Table 4). 
It did not correlate with HER-2 expression (P = 0.013) or 
with FRA-1 (P = 0.2443, Table 5). 
FRA-1 expression was always evident around ductal struc-
tures, thus strongly marking the basal membrane (Figure 3). 
Ductal cells were usually negative, but in normal ductal struc-
tures, some scattered elements showed nuclear-exclusive 
staining. In one third of the cases with normal breast tissue, 
more than 10% of the preserved ductal cells expressed FRA-1. 
However, the majority of non-proliferative lesions, including 
papillary lesions, adenosis, apocrine metaplasia and colum-
nar alterations remained diffusely negative. The reactivity to 
FRA-1 tended to be more intense and diffusely distributed 
in atypical and malignant lesions (13 out of 21 cases), with 
positive associations with atypia and malignancy (P = 0.04, 
Table 4). FRA-1 expression was also strongly associated with 
HER-2 expression (P < 0.001; Table 5).
Variable
BI-RADS
Total P-value
Morphological assessment
Total P-value
4A 4B or 4C Benign
Atypical
malignant
FRA-1
Negative 48 (69.6%) 28 (48.3%) 76 (59.8%) 0.0241 68 (64.2%) 8 (38.1%) 76 (59.8%)
0.0475Positive 21 (30.4%) 30 (51.7%) 51 (40.2%) 38 (35.8%) 13 (61.9%) 51 (40.2%)
Total 69 (100%) 58 (100%) 127 (100%) 106 (100%) 21 (100%) 127 (100%)
HER-2 
Negative 64 (92.8%) 45 (77.6%) 109 (85.8%) 0.0288 96 (90.6%) 13 (61.9%) 109 (85.8%)
0.0020Positive 5 (7.2%) 13 (22.4%) 18  (14.2%) 10 (9.4%) 8 (38.1%) 18 (14.2%)
Total 69 (100%) 58 (100%) 127 (100%) 106 (100%) 21 (100%) 127 (100.0%)
Claudin
Negative 9 (13%) 9 (15.5%) 18 (14.2%) 0.8865 17 (16%) 1 (4.8%) 18 (14.2%)
0.3040Positive 60 (87%) 49 (84.5%) 109 (85.8%) 89 (84%) 20 (95.2%) 109 (85.8%)
Total 69 (100%) 58 (100%) 127 (100%) 106 (100%) 21 (100%) 127 (100.0%)
Paxillin
Negative 31 (44.9%) 31 (53.4%) 62 (48.8%) 0.4362 53 (50%) 9 (42.9%) 62 (48.8%)
0.7190Positive 38 (55.1%) 27 (46.6%) 65 (51.2%) 53 (50%) 12 (57.1%) 65 (51.2%)
Total 69 (100%) 58 (100%) 127 (100%) 106 (100%) 21 (100%) 127 (100.0%)
Table 4. Correlation of HER-2, paxillin, claudin and FRA-1 results with morphological and radiological variables
BI-RADS = Breast Imaging Reporting and Data System Atlas.
Figure 1. Claudin-4 immunoexpression in non-nodular breast lesions: 
(A) ductal lobular terminal unit; (B) fibrosclerosis; (C) attenuation in 
fibroadenosis; (D) papilloma; (E) hyperplasia of usual type; (F and G) 
atypical hyperplasia; and (H and I) ductal carcinoma in situ. 
 A
 D
 G  H  I
 B
 E  F
 C
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DISCUSSION
Analysis on non-nodular lesions of the breast encompasses a 
large range of entities since, aside from the premalignant enti-
ties, many benign lesions and alterations may present microcalci-
fications over time. Vacuum-assisted or core biopsies are usually 
indicated in cases that are radiologically classified as BI-RADS 4. 
According to the BI-RADS classification, this category includes a 
wide range of lesions: category 4A is defined as “findings need-
ing intervention with a low suspicion of malignancy”; category 
4B includes “lesions with an intermediate suspicion of malig-
nancy” and the new category 4C consists of lesions with “find-
ings of moderate concern, but not classic for malignancy”.22 
Variables
HER-2
Total P-value
Paxillin
Total P-value
Negative Positive Negative Positive
FRA-1
Negative 72 (66.1%) 4 (22.2%) 76 (59.8%)
0.0011
42 (55.3%) 34 (44.7%) 76 (100%)
0.013Positive 37 (33.9%) 14 (77.8%) 51 (40.2%) 20 (39.2%) 31 (60.8%) 51 (100%)
Total 109 (100%) 18 (100%) 127 (100%) 62 (48.8%) 65 (51.2%) 127 (100%)
Claudin
Negative 18 (16.5%) 0 (0%) 18 (14.2%)
0.0734
18 (29%) 0 (0%) 18 (14.2%)
< 0.001Positive 91 (83.5%) 18 (100%) 109 (85.8%) 44 (71%) 65 (100%) 109 (85.8%)
Total 109 (100%) 18 (100%) 127 (100%) 62 (100%) 65 (100%) 127 (100%)
Paxillin
Negative 56 (51.4%) 6 (33.3%) 62 (48.8%)
0.2443Positive 53 (48.6%) 12 (66.7%) 65 (51.2%)
Total 109 (100%) 18 (100%) 127 (100%)
Table 5. Correlation of HER-2, paxillin, claudin and FRA-1 results 
Figure 2. Paxillin immunoexpression in non-nodular breast lesions: 
(A) ductal lobular terminal unit; (B) fibrosclerosis; (C) attenuation 
in fibroadenosis; (D) columnar alteration; (E) papilloma; (F) 
hyperplasia of usual type; (G) atypical hyperplasia; and (H and I) 
ductal carcinoma in situ.
Figure 3. FRA-1 immunoexpression in non-nodular breast 
lesions: (A) ductal lobular terminal unit; (B) fibrosclerosis; (C) 
columnar alteration; (D) hyperplasia of usual type; (E) atypical 
ductal hyperplasia; (F and G) positive and negative ductal 
carcinoma in situ; and (H and I) same area of ductal carcinoma 
in situ, negative for FRA-1 and positive for HER-2 expression. 
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Interestingly, the results from the morphological diagnosis were 
statistically associated with these BI-RADS categories at the same 
non-nodular lesions, and this became more significant when cat-
egories B and C were merged together. Since the adhesion prop-
erties of epithelial mammary cells are linked to basal membrane 
status and also to the surrounding extracellular matrix, non-
nodular lesions seem to be an ideal vehicle for pinpointing early 
events in stromal and epithelial cells that may only have acquired 
subtly compromised adhesion properties. 
We also had the opportunity to investigate the expression 
of these proteins in many specimens of virtually nearly normal 
breast tissue, which were collected and fixed in accordance with 
the best recommendations. These provided a good description 
of claudin, FRA-1 and paxillin distribution in non-proliferative 
lesions, as well as in nearly normal breast tissue. 
In this regard, we found some imbalance of adhesion pro-
tein expression even in the benign cases. Claudin-4 expression, 
for instance, was negative in 17 cases of non-malignant breast 
lesions, especially those harboring apocrine metaplasia and ade-
nosis. Another important finding was that claudin-4 expression 
was maintained through the progression to atypical lesions and 
in situ carcinomas, thus resulting in a larger contingent of posi-
tive samples in our series and therefore lacking correlation with 
morphological or radiological categories. Since the recent find-
ings of loss of claudin expression have mostly been linked to 
estrogen-negative and high-grade carcinomas20 and/or aggres-
sive triple negative cases, it can be inferred that claudin-4 expres-
sion imbalance is related most exclusively to precursor lesions of 
highly aggressive tumors such as high-grade ductal carcinoma 
in situ.23 It seems that these events were not sampled in our series, 
or that they occur later on in breast carcinogenesis. 
FRA-1 expression in normal and non-neoplastic breast tis-
sue showed nuclear immunoreactivity, as reported by Song 
et  al.24 We did not find any example of cytoplasmic reactivity 
for FRA-1, even at in our single case of invasive carcinoma. This 
may be explained by the fact that this particular case was a muci-
nous well-differentiated carcinoma. However, we found a shift 
between benign and malignant lesions, particularly when atypi-
cal cases were merged with in situ carcinomas. While one third of 
the benign cases were FRA-1 positive, over 61% of the malignant 
cases showed some nuclear reaction to FRA-1 (P = 0.0475), con-
cordant with the findings of Song et al.24 
Interestingly, FRA-1 expression also correlated with BI-RADS 
classification. The possible role of FRA-1 in early carcinogenesis 
was previously demonstrated when, in a larger series of in situ 
and invasive nodular cases, the frequency of FRA-1 expression 
in invasive cancer was lower than it was in in situ lesions.19 It 
seems that in situ carcinomas harbor the highest possible amount 
of FRA-1 nuclear expression and, according to other reports,24,25 
the invasion process may be accompanied by concomitant detec-
tion of cytoplasmic FRA-1 and diminution of FRA-1 expres-
sion, in comparison with in situ cases. One possible explana-
tion for FRA-1 detection in cytoplasm could be that extracellular 
secretion of FRA-1 may occur, internalized by certain neoplas-
tic cells, given that the tumor-associated macrophages that are 
present in invasive tumors intensively express FRA-1 and there-
fore indirectly support invasion and progression of carcinomas 
cells.26 Alternatively, the higher frequency of FRA-1 expression in 
membrane-restricted lesions should be addressed, in the light of 
reports on impressive FRA-1 effects relating to invasiveness, cell 
motility, aggressiveness and regulation of proteins implicated in 
tumor progression, which have been described in cultured breast 
tissue cells.27 It is possible that the momentum shortly before the 
impressive shift from in situ to invasive carcinoma, with focal 
infiltration, constitutes the most demanding situation for nuclear 
FRA-1 production. 
In normal mammary cells, paxillin had previously seldom 
been described in humans, and the few reports available are 
rather similar to what we have reported here.12 On the other 
hand, invasive ductal carcinomas showed expression of 27.7% 
(short S) to 50%.12 We were able to describe paxillin expres-
sion with a wider range of functional alterations, and half of the 
benign cases were positive. In contrast to another report,12 we 
did not find any association between paxillin expression and 
progression to malignancy or BI-RADS classification. However, 
when assessed in cytological smears, paxillin failed to reach any 
concordance with invasion or prognostic variables.28 It remains 
unclear whether paxillin may be associated with invasion, since 
it regulates focal adhesion kinase (FAK) function,29 which is a 
marker of malignant transformation rather than invasion.30 
A substantial set of malignant and premalignant cases needs to 
be evaluated in order to provide further responses to this ques-
tion, since paxillin expression was correlated with claudin and 
FRA-1 expression in our cases (P < 0.001 and 0.013, respectively). 
It appears that adhesion signals and complex cellular pro-
tein complexes are somehow interrelated, and that subtle imbal-
ance of one settlement may interfere with others. Alternatively, 
it is possible that cellular signaling aiming towards switching the 
adhesion status is launched in a coordinated manner, which may 
affect some, if not all, adhesion complexes in a cascade. 
There are several reports in the literature regarding inter-
actions between HER-2 expression and adhesion molecules. 
Paxillin expression was found to correlate with HER-2 gene 
amplification in 314 cases of invasive carcinoma, which led 
to speculation about whether paxillin might be a marker that 
could influence the predictive value of HER-2 regarding the 
response to adjuvant treatment.21 We could not identify such 
a correlation, since the majority of our cases comprised benign 
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and negative HER-2 samples, concordant with the findings of 
Madan et al.12 Claudin-4 was found to correlate with HER-2 
immunohistochemical expression in 299 cases of invasive duc-
tal carcinoma,20 but another report did not find this correla-
tion in 412 tumors.31 In our series, this correlation was also not 
found (P = 0.0734). It seems that the larger contingent of non-
neoplastic cases impeded a more specific correlation between 
these two variables. 
Finally, we were able to report a statistically significant cor-
relation between HER-2 and FRA-1 expression (P < 0.001). 
Since both of these variables also statistically correlated with the 
radiological and morphological results in this set of non-nodu-
lar breast lesions, a larger series of premalignant and malignant 
cases is essential in order to clarify the possible significance of 
these findings. 
CONCLUSION
We conclude that, although already present in smaller amounts, 
imbalance of adhesion molecules is not necessarily prevalent 
in non-nodular breast lesions. Moreover, since FRA-1 expres-
sion reached statistically significant correlations with radiologi-
cal and morphological diagnoses and with HER-2 status, perhaps 
this expression should be evaluated in a larger series, in order to 
investigate its potential predictive role in this setting.
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